Tuesday, August 2, 2016

Merck's KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

… of lung cancer than die of colon,
breast, and prostate cancers combined. The two main types of lung cancer
are non-small … advanced non-small cell lung cancer (NSCLC) whose tumors express
PD-L1 as determined …

No comments:

Post a Comment